Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.

The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.